Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer. July 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00243 Journal of Clinical Oncology - published online before print July 5, 2023 PMID: 37406455 Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer Antonio C. Wolff , MD, FACP, FASCO1,2xAntonio C. WolffSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD https://doi.org/10.1200/JCO.23.00243 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn the companion to this article, Paik et al1 demonstrated that a 21-gene recurrence score assay identified the patients expected to benefit from the addition of adjuvant chemotherapy to 5 years of tamoxifen in patients with estrogen receptor–positive, node-negative breast cancer. These findings ushered a new era that increasingly focuses on optimizing therapies for all patients (more for some, less for others) and on improving the accuracy and reproducibility of biomarkers used for clinical decision making.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Multigene Predictor for Chemotherapy Response in Breast CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Antonio C. WolffResearch Funding: Genentech (Inst), Merck Sharp & Dohme (Inst), Array BioPharma (Inst)Patents, Royalties, Other Intellectual Property: Antonio Wolff has been named as an inventor on one or more issued patents or pending patent applications related to methylation in breast cancer, has assigned his rights to JHU, and participates in a royalty sharing agreement with JHUNo other potential conflicts of interest were reported. Companion Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer